Stanford stem cell experts highlight “inherent flaw” in drug development system – Scope (blog)
|
Stanford stem cell experts highlight “inherent flaw” in drug development system
Scope (blog) Academic institutions are in a much better position than pharmaceutical companies to make the best decisions about which therapies deserve further development. That was the underlying message from a pair of Stanford researchers at a panel on stem cell … |
|
US clinics avoiding government oversight of ‘stem cell‘ treatments
Medical Xpress Clinics across the United States are advertising stem cell treatments that attempt to take advantage of what they perceive as exceptions in FDA regulations, according to bioethicist Leigh G. Turner, PhD, Associate Professor, University of Minnesota … |
|
US clinics avoiding government oversight of ‘stem cell‘ treatments
Medical Xpress Clinics across the United States are advertising stem cell treatments that attempt to take advantage of what they perceive as exceptions in FDA regulations, according to bioethicist Leigh G. Turner, PhD, Associate Professor, University of Minnesota … |
Regulatory Focus |
German Regulators Decry Lack of Trial Transparency in Look at Stem Cell …
Regulatory Focus The German Institute for Quality and Efficiency in Health Care (IQWiG) has found recent clinical data on the use of stem cell transplantation to treat multiple myeloma—a rare and deadly form of cancer—to be inconclusive. |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
CNNMoney Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
CNNMoney Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
MarketWatch Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |
|
OncoMed Publishes Data on Tarextumab’s Anti-Cancer Stem Cell Activity in …
MarketWatch Preclinical studies have suggested that tarextumab exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, tarextumab appears to have anti-cancer stem cell effects, and (2) tarextumab affects pericytes, impacting stromal and … |